Pune, India -- (SBWIRE) -- 01/10/2019 -- The report considers the present scenario of the global premature ejaculation market and its in-depth analysis for the period 2017-2022. It includes a detailed study of growth drivers, trends, and restraints. The report also profiles the leading vendors in the market and other key vendors.

Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals and Allergan are the leading companies dominating the premature ejaculation market. The global premature ejaculation (PE) market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016-2022. A high burden of PE prevalence and associated chronic condition, which can, in turn, poses as a high-risk factor for the occurrence of this disease is the key market driver for the premature ejaculation market in both developing and developed countries.

Get Request Sample Copy of This Global Premature Ejacualtion Market Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1730885.

Regionally, the US is the main contributor to the global PE market. Despite the absence of PE drug in the US, the market in North America retains dominant share because of wide accessibility to PE off-labels and OTC drugs. In terms of route of administration, the oral drugs segment contributes a dominant share of nearly three-fourths of the global market.

Major vendors profiled in the report are as following: Innovus Pharma, Plethora Solutions, Absorption Pharmaceuticals, Allergan

Other prominent vendors include Menarini, GlaxoSmithKline, Ixchelsis, Dong-A Pharmaceutical, NeuroHealing Pharmaceuticals.

Major trends, drivers, and restraints for each geography are included in the report.Premature ejaculation (PE) is a male sexual dysfunction, which is characterized by the inability to delay ejaculation for more than one minute after penetration or sexual stimulation. The condition is associated with uncontrolled ejaculation either before or shortly after sexual penetration, or with minimal sexual stimulation.

Order a copy of this Premature Ejacualtion market report @ https://www.reportsnreports.com/purchase.aspx?name=1730885.

The global premature ejaculation market is expected to cross $1.9 billion, growing impressively at a CAGR of 8.9% during the period 2016-2022. Increasing disease awareness, growing patient willingness to seek pharmaceutical therapy assistance for disease management and increasing presence of favorable guidelines, which recommended the use of drugs as first-line therapy for treatment of PE, will augment market prospects during the forecast period.

The report provides a holistic view of the global premature ejaculation market, the companies involved in the market, and the factors driving its growth. The report also provides information about the latest trends that are likely to become strong market driving forces over the next five years. This report also provides the Porter?s Five Forces analysis along with a description of each force and its impact on the market. Further, the report also provides complete value chain analysis of the global market.

Increase in prevalence of chronic diseases, low-effectiveness of non-pharmacological treatment, and a wide accessibility to premature ejaculation OTC drugs and generic off-label drugs are the prime factors that are going to escalate the market growth during the forecast period. Furthermore, pharmaceutical advances in PE drug formulation technology, emphasis on clinical progress of love hormone receptor antagonists, and launch of premature ejaculation treatment awareness campaigns are the latest trends that are likely to positively impact the market. The report also provides the key restraints of the market.

Get Discount on Premature Ejacualtion Market Research @ https://www.reportsnreports.com/contacts/discount.aspx?name=1730885.

In terms of mechanism of action (MOA), the global PE market broad segments include SSRIs, PDE5 inhibitors, and amide anesthetics. In 2016, the SSRIs segment dominated the market. This segment is anticipated to retain its dominance till the end of forecast period. The amide anesthetics segment, which occupied low share in 2016, is anticipated to witness higher growth than the other drug MOAs segment during the period 2016-2022.

The premature ejaculation market in North America is the largest due to high prevalent PE population. The US occupies approximately 90% of the PE market in North America due to the high population density and comparably higher utilization of off-label and OTC PE products. Similarly, the UK, Germany, France, Spain, and Italy are the leading markets for PE therapies in the European region. The market in APAC is likely to witness the highest growth rate during the forecast period. A significant increase in PE incidence due to growing burden of chronic conditions, which, in turn, is associated with the high risk of PE occurrence is expected to boost the market growth in this region. The prevalence of PE in the Middle East countries and Latin America is estimated to be lowest than other regions. The market, however, is anticipated to witness a moderate growth rate in these regions.

Browse All Latest Healthcare Market Research Reports @ https://www.reportsnreports.com/market-research/healthcare/.

About ReportsnReports.com
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact Us:
Vishal Kalra
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com